Loading...
•
Dec 31, 2024
Immunocore Q4 2024 Earnings Report
Immunocore's Q4 2024 financial results were released, featuring KIMMTRAK sales growth and pipeline advancements.
Key Takeaways
Immunocore reported Q4 2024 financial results, highlighted by $84.1 million in KIMMTRAK net sales. The company progressed its clinical pipeline and expanded into autoimmune diseases, supported by a strong cash position.
KIMMTRAK Q4 net sales reached $84.1 million, with $310.0 million for the full year 2024.
Continued KIMMTRAK lifecycle management with Phase 3 trials in additional melanoma indications.
Advanced PRAME portfolio, including the first patient randomized in Phase 3 PRISM-MEL-301.
First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers.
Revenue by Segment
Forward Guidance
Immunocore anticipates continued growth in 2025, focusing on expanding KIMMTRAK's market presence and advancing its clinical pipeline.
Positive Outlook
- Expects incremental growth in metastatic uveal melanoma driven by further expansion into the U.S. community and additional launches.
- Will continue to enroll patients in the Phase 3 TEBE-AM trial for advanced cutaneous melanoma, with data expected in 2026.
- Will continue to enroll patients in the Phase 3 ATOM trial for adjuvant uveal melanoma.
- Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025.
- CTA/IND on track for IMC-S118AI (type 1 diabetes candidate) in 2H 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...